Can a crocosmia bulb compound tame type 2 diabetes?

NCT ID NCT05826054

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This early trial tests montbretin A, a compound extracted from crocosmia plant bulbs, in people with type 2 diabetes and in healthy volunteers. The main goal is to find a safe dose and see if it causes fewer stomach side effects than standard diabetes medications. Participants take increasing amounts of montbretin A over two weeks, alongside a standard meal, and undergo blood tests and heart checks. The study focuses on safety and tolerability, not yet on how well it controls blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Montbretin A, a purified compound from crocosmia plant bulbs, taken as a dietary supplement
What this could lead to
If safe and well-tolerated, montbretin A could become a natural option to help manage blood sugar after meals in type 2 diabetes, with fewer stomach side effects than current drugs.
What could go wrong
This is an early, small Phase 1 trial focused on safety, not effectiveness. Montbretin A may cause digestive issues like gas or diarrhea, and it might not prove better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

15 people

The number who actually took part.

Started

Dec 2023

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, age ≤ 65 years; ≥19 years; * Have diagnosed type-2 diabetes mellitus with HbA1C between 6.5% to 11% that is currently managed by diet and no other medications or healthy volunteers defined as not having diagnosis of type-2 diabetes mellitus. * Have routine and normal dietary habits that include three meals a day; * Normal hematological parameters as determined through an in-person screening blood draw including HbA1C \>4.0% in healthy volunteers. * Use of an effective barrier method of birth control throughout the study, surgical sterility, or menopausal for at least 2 years; * In the study team's opinion, capable of understanding the visit schedule requirement and study medication dosing requirements. * Be able to avoid all supplements that affect blood sugar for the duration of the study eg. chromium, bitter melon, thiamine, berberine, alpha-lipoic acid, devil's claw, horse chestnut, fenugreek, ginseng, psyllium, cinnamon, garlic and panax. Exclusion Criteria: * Currently in poor health, as determined by the study doctor * Currently on medication, except vitamins and/or birth control * Not eating three regular meals a day * Current or a history of impairment of gastro-intestinal function, including but not limited to inflammatory bowel disease, colonic ulceration, and/or partial intestinal obstruction * Travelled to a foreign country less than four (4) weeks prior to study entry; * Surgery less than four (4) weeks a prior to study entry; * Pregnant or lactating women; * Planning to participate in other investigational drugs while participating in the study; * Known allergy to study medication or its components (non-medicinal ingredients); and * A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • VCHRI Clinical Research Unit

    Vancouver, British Columbia, V5Y2S7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.